Renaissance Technologies LLC lowered its stake in shares of ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report) by 6.1% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 220,510 shares of the company’s stock after selling 14,296 shares during the period. Renaissance Technologies LLC’s holdings in ProPhase Labs were worth $922,000 as of its most recent SEC filing.
Separately, Vanguard Group Inc. boosted its stake in shares of ProPhase Labs by 1.5% in the 1st quarter. Vanguard Group Inc. now owns 618,763 shares of the company’s stock worth $4,003,000 after buying an additional 9,416 shares during the last quarter. 9.45% of the stock is owned by hedge funds and other institutional investors.
ProPhase Labs Stock Up 0.4 %
PRPH opened at $2.47 on Tuesday. ProPhase Labs, Inc. has a 12 month low of $2.00 and a 12 month high of $7.48. The company has a 50 day moving average of $2.57 and a 200 day moving average of $4.05. The company has a current ratio of 1.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.33. The company has a market cap of $47.13 million, a PE ratio of -2.29 and a beta of -0.12.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded shares of ProPhase Labs to a “sell” rating in a research note on Wednesday, June 26th.
Get Our Latest Report on ProPhase Labs
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Read More
- Five stocks we like better than ProPhase Labs
- Best Aerospace Stocks Investing
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Dividend Payout Ratio Calculator
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- What is MarketRank™? How to Use it
- RPM International Thrives in Rate-Cut Driven Construction Rally
Want to see what other hedge funds are holding PRPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProPhase Labs, Inc. (NASDAQ:PRPH – Free Report).
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.